BRIEF published on 09/18/2024 at 07:05, 1 month 11 days ago Relief Therapeutics achève la phase clinique de l'étude RLF-OD032 Étude Clinique RLF-OD032 Biodisponibilité Phénylcétonurie Dichlorhydrate De Saproptérine
BRIEF published on 09/18/2024 at 07:05, 1 month 11 days ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 month 11 days ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 month 27 days ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 1 month 27 days ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 month 27 days ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 month 30 days ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 1 month 30 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 month 30 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 2 months 24 days ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
Published on 10/29/2024 at 22:10, 2 hours 12 minutes ago Electric Metals Announces DSU and Stock Option Grant
Published on 10/29/2024 at 20:15, 4 hours 7 minutes ago Tenth Avenue Petroleum Executes Definitive Agreement To Acquire Low Decline, Production In Southern Alberta
Published on 10/29/2024 at 19:30, 4 hours 52 minutes ago “Bogotá Your Home”: A Showcase of Bogotá’s New Image at COP16
Published on 10/30/2024 at 00:17, 5 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: September 2024 quarter update
Published on 10/29/2024 at 23:56, 26 minutes ago grenke publishes preliminary figures for the third quarter of 2024
Published on 10/29/2024 at 20:34, 3 hours 48 minutes ago EQS-Adhoc: Daimler Truck Holding AG: Release
Published on 10/29/2024 at 19:08, 5 hours 14 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 10/29/2024 at 17:40, 6 hours 42 minutes ago Mersen to acquire Bar-Lo carbon products to consolidate its material strategy in the United States
Published on 10/29/2024 at 17:40, 6 hours 42 minutes ago Mersen acquiert Bar-Lo Carbon Products pour consolider sa stratégie matériaux aux États-Unis